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Background: The endothelial cell dysfunction observed in preeclampsia (PE) may be induced by CD40/CD40L
signaling. This study investigated the role of CD40/CD40L in the pathogenesis of PE by comparing the effect of
maternal serum obtained from healthy pregnant women and PE patients on HUVEC cell growth, apoptosis and
CD40/CD40L expression.
Methods: Maternal serum was obtained from 20 patients with PE (PE group) as well as 20 healthy pregnant women
(control group). The human umbilical endothelial cell line, CRL1730, was cultured in the presence of maternal serum for
24, 48, and 72 h after which cell growth and apoptosis were assessed by MTT and flow cytometry analysis, respectively.
CD40/CD40L expression was determined using flow cytometry and RT-PCR analyses.
Results: As compared to CRL1730 cells treated with control sera, those treated with PE sera had altered morphology,
decreased cell growth, increased apoptosis and greater CD40/CD40L protein and mRNA expression. Stimulation of
CD40/CD40L protein and mRNA expression by PE sera was greatest at 24 h.
Conclusions: PE sera may induce endothelial cell damage possibly through increased CD40/CD40L expression in early-
onset PE. Further studies are necessary to determine the factor(s) in PE sera responsible for the observed changes in
endothelial cell viability.
Keywords: Preeclampsia, Endothelial dysfunction, CD40/CD40L, Human umbilical cord endothelial cellsBackground
Early-onset preeclampsia (PE) occurs within 34 weeks of
pregnancy [1], and is a major cause of maternal and
perinatal morbidity and mortality [2,3]. Although ensur-
ing maternal safety, early pregnancy termination, the
only treatment for PE, often results in serious neonatal
developmental complications and sequelae. Therefore,
prevention and early detection of PE is crucial.
Although the etiology of PE remains unknown, endo-
thelial cell dysfunction plays an important role in its
pathogenesis [4] and may be mediated by CD40/CD40L
signal transduction [5]. In porcine coronary arteries,
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reproduction in any medium, provided the or(eNOS) mRNA expression and increased O2
- [6]. Fur-
thermore, increased soluble CD40L and upregulated
CD40/CD40L expression were detected in the whole-
blood platelets and monocytes of women with PE [7,8].
CD40, a transmembrane glycoprotein, and its ligand,
CD40L, a member of the TNF superfamily of molecules,
are widely distributed in human endothelial cells,
smooth muscle cells, lymphocytes, and activated plate-
lets [9]. CD40/CD40L plays an important role in antigen
presentation and autoimmune disease [10], and its sig-
naling induces the expression of adhesion molecules and
metalloproteinases [11]. In addition, CD40-CD40L inter-
actions transduce immune and inflammatory signals,
promoting the generation of Th1 and Th2 cytokines and
stimulating blood cells to produce IL-1β precursors and
IL-β-converting enzymes [12]. Increased IL-1 activity
prolongs the inflammatory responses, resulting in endo-
thelial cell damage [13]. Furthermore, Lin et al. [5]This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pression and oxidative endothelial cell damage in human
umbilical vascular endothelial cells (HUVECs).
This study sought to explore the role of CD40/CD40L
in the pathogenesis of early-onset PE by determining the
effects of maternal serum obtained from patients with
early-onset PE on CD40/CD40L signaling in the human
umbilical endothelial cell line, CRL1730. Specifically, the
effects of maternal serum isolated from PE patients and
healthy pregnant women on CRL1730 viability, apop-
tosis, and CD40/CD40L expression were determined.Methods
Criteria for selecting pregnant women and the collection
of blood specimens
From October 2008 to May 2010, 20 patients with PE
and 20 randomly selected healthy pregnant women were
recruited at the First Clinical College of Harbin Medical
University. Early-onset PE was diagnosed as described
by Valensise et al. [14]. The following inclusion criteria
for the PE group were used in the present study: preg-
nant at gestational age of 20 to 34 weeks, blood pressure
≥140/90 mmHg, urine protein ≥ 300 mg/24 h or immu-
noreactive urine protein with epigastric pain and head-
ache. The participants were all primiparous with a single
fetus, had no history of hypertension and renal disease
before pregnancy, and were free of placenta previa, early
placental abruption or other obstetric complications. Six
hours after fasting, 10 mL venous blood was collected in
all study participants. The serum was isolated by centri-
fugation at 3000 r/min for 5 min after which the super-
natant was collected, aliquoted into 1.5 mL Eppendorf
tubes, and stored at -80°C. This study was approved by
the Institutional Ethics Committee of the First Affiliated
Hospital, Harbin Medical University, and patient consent
was obtained from each participant.The culture and treatment of CRL1730 human umbilical
vein endothelial cells (HUVECs)
The human umbilical vein endothelial cell line,
CRL1730, was purchased from ATCC (Manassas, VA).
CRL1730 cells were cultured in F-12 K medium (ATCC)
containing endothelial cell growth supplement (ECGS;
Sciencell; Carlsbad, CA) and 10% fetal bovine serum
(FBS; Gibco; Carlsbad, CA) in a 5% CO2, 37°C incubator.
After reaching confluency, the cells were subsequently
cultured at a 1:2 ratio and passaged every other day.
After reaching 80% confluency, the cells were synchro-
nized by starvation in serum-free medium for 24 h. In
the control group, the cells were cultured in medium
containing 10% maternal serum obtained from healthy
pregnant women for 24, 48 and 72 h. In the PE group,
the cells were cultured in the medium containing 10%maternal serum obtained from early-onset PE patients
for 24, 48 and 72 h.
MTT assay
The cells were digested to form a single-cell suspension in
medium containing 10% FBS before they were seeded onto
96-well plates at a density of 3000 cells/200 μL/well. After
24 h, the cells were cultured in serum-free medium for
24 h after which non-adherent cells were removed by
washing with PBS. Cells from every sample were plated in
5 wells, and control wells were added into the medium
with 10% of the corresponding maternal serum in addition
to MTT (AMRESCO, Solon, OH) and dimethyl sulfoxide
(DMSO; AMRESCO). After 24, 48, and 72 h, the medium
was replaced with 200 μL new medium containing 10%
FBS, and 20 μL MTT solution was added at a final con-
centration of 5 mg/mL. The cells were then incubated for
4 h before the supernatant was discarded after which 150
μL DMSO was added before shaking for 10 min until the
crystals were fully dissolved. Absorbance was measured at
490 nm using a TECAN microplate reader (Männedorf,
Switzerland).
Annexin V staining to assess CRL1730 apoptosis
CRL1730 cells were digested with trypsin, and the cell
suspension was adjusted with medium to 2.5 × 105 cells/
mL. Cells were isolated from a 1-mL cell suspension by
centrifugation at 1000 r/min for 5 min after which they
were washed with PBS. After centrifugation at 1000 r/
min for 5 min, apoptosis was determined using the Fas-
calibur apoptosis kit (NeoBioscience, Cambridge, MA).
Before measurement, 5 μL of Annexin V and 10 μL of
propidium iodide (PI) were added for 10 min. Three
negative control groups were included: one without dye,
one with 5 μL Annexin V alone, and one with 10 μL PI
alone.
Flow cytometry to assess CD40/CD40L expression
After reaching 80% confluency in six-well plates, CRL1730
cells were digested with trypsin and collected by centrifu-
gation at 1000 r/min for 5 min before washing twice with
PBS to remove cell debris. The cells were resuspended in
F-12 K culture medium containing 10% FBS, and the cell
concentration was adjusted to 5 × 105 cells/mL. Direct
fluorescence detection was performed by incubating 100
μL of staining buffer (PBS with 2% FCS, 0.1% NaN3 and 5
μL of FITC-conjugated anti-CD40 or CD40L monoclonal
antibody [BD Bioscience, USA]) for 30 min at 4°C before
centrifugation at 1000 rpm for 5 min. The supernatant
was discarded, and the cells were washed twice with cold
PBS prior to centrifugation at 1000 rpm for 5 min. After
fixation with 500 μL of 1% paraformaldehyde (PFA),
CD40/CD40L expression was determined using flow cyto-
metry (BD Biosciences) by counting 10,000 cells. Mean
Table 1 Comparison of baseline characteristics between
the normal and PE pregnant groups
Control(N= 20) PE(N= 20) P value
Age (y) 27.50 ± 2.82 28.65 ± 3.20 0.235
Gestation (weeks) 31.60 ± 1.73 31.60 ± 1.73 0.229
Body weight (kg) 69.25 ± 7.20 70.10 ± 6.80 0.703
Body height (m) 1.61 ± 0.04 1.60 ± 0.03 0.383
BMI (kg/m2) 26.69 ± 2.90 27.36 ± 2.96 0.477
Continuous variables were presented as mean ± SD, and the groups were
compared using Independent sample t-tests; PE, preeclampsia; BMI, body mass
index
*P< 0.05
Figure 1 Effects of normal pregnant and PE sera on CRL1730
cell morphology. CRL1730 cell morphology upon stimulation with
maternal sera obtained from A) normal pregnant and B) PE patients
(300× magnification). A representative image from three
independent experiments is shown
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level of CD40/CD40L expression in CRL1730 cells relative
to the standard normal reference fluorescence intensity
(the international unit of light intensity, Cd).
Reverse transcription polymerase chain reaction (RT-PCR)
analysis
Trizol (Molecular Research Center, Inc., Cincinnati, OH)
one-step extraction was performed to isolate total RNA
from CRL1730 cells. cDNA was obtained through re-
verse transcription using the Roche first-strand cDNA
synthesis kit (Roche; San Francisco, CA). In addition to
a dNTP mix (TaKaRa Biotechnology, Dalian, China) and
Taq enzyme (TaKaRa), the following PCR primers were
synthesized by Invitrogen (Shanghai): CD40, forward 5’-
TTGGTGGTGGTGGTGTTG-3’ and reverse 5’-
GCATCTGTGTATATGGCTTCC-3’ (124 bp); CD40L,
forward 5’-CCTCTGCCACCTTCTCTG-3’ and reverse
5’-TCTTCTATCTTGTCCAACCTTC-3’ (213 bp); and
GAPDH, forward 5’-ACGGATTTGGTCGTATTGGG-3’
and reverse 5’-TCCTGGAAGATGGTGATGGG-3’
(202 bp). Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA expression was used as an internal
reference. The PCR amplification reaction conditions
were as follows: pre-denaturation at 94°C for 3 min, 30
amplification cycles at 94°C for 30 s, 63°C for 30 s (for
CD40) or 60°C for 30 s (for CD40L), and 72°C for 30 s,
and a final extension at 72°C for 7 min. Agarose gel elec-
trophoresis (2%) was observed using an imaging system
(AlphaInnotech, Johannesburg, South Africa). Density
scanning of the electrophoretic bands was performed,
and relative target mRNA expression was determined
using the absorbance CD40/CD40L divided by that of
GAPDH.
Statistical methods
Independent sample t-tests, which compare the mean
scores of two groups for a given variable, were used to
compare the effect of baseline characteristics between the
normal pregnant and PE groups. Data was presented as
mean±SD. Repeated ANOVA was used to examine the
difference of each indices at 24, 48 and 72 h between the
two groups. P-values< 0.05 were considered statistically
significant. Statistic analyses were performed using SAS
9.2 statistics software (SAS Institute Inc., Cary, NC, USA).
Results
Participant baseline characteristics
Forty pregnant women, including 20 patients with PE (PE
group) and 20 healthy pregnant women (control group),
were enrolled in this study. As shown in Table 1, no sig-
nificant differences in age, body weight and height, and
BMI were found between the two groups. Furthermore,no difference in the gestation week during which the
blood sample was obtained was observed (Table 1).Effects of normal pregnant and PE sera on CRL1730 cell
morphology
As shown in Figure 1, the influence of patient sera on
CRL1730 morphology was determined using inverted mi-
croscopy. CRL1730 cells cultured in the presence of con-
trol maternal sera were arranged in a mosaic-like
monolayer; the cells were round and flat or polygonal with
a cobblestone appearance (Figure 1A). CRL1730 cells cul-
tured in maternal sera obtained from PE patients displayed
altered morphology. Specifically, the cells were sparsely
distributed with blurred boundaries between the nucleus
and the cytoplasm; dark cytoplasmic granules were also
observed (Figure 1B).Effects of normal pregnant and PE sera on CRL1730
growth and apoptosis
As shown in Figure 2, CRL1730 cell growth significantly
increased over time in both groups (P <0.05). However, as
compared with the cells treated with control maternal
sera, CRL1730 cell growth in the PE group was signifi-
cantly decreased (P <0.01). These data indicated growth
inhibition by early-onset PE serum possibly due to cell
damage.
Figure 2 CRL1730 cell growth after culture with sera obtained
from the normal pregnant patients or those with PE.
Continuous variables were presented as mean± SD and comparison
of effect between two groups over time was performed by repeated
measures of ANOVA and difference in growth between two groups
over time was significant (P< 0.001). n = 20 for each group
Figure 3 Effects of normal and PE sera on CRL1730 cell apoptosis. Ap
normal and PE pregnant women using Annexin V and PI double staining m
group; C) 72-h normal pregnant group; D) 24-h PE group; E) 48-h PE group
independent experiments is shown
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PE serum was due to apoptosis, Annexin-V staining was
undertaken (Figures 3 and 4). Representative results for
each group and time point assessed are found in Figure 3.
Compared with the cells treated with control maternal
sera, significantly increased apoptosis was observed in
those treated with PE sera at each time point analyzed
(P <0.01), indicating that PE serum promoted apoptosis
(Figure 4). However, the apoptosis rates in the PE group
significantly decreased with time (P <0.05) while no dif-
ference was found in the control group.
Effects of normal pregnant and PE sera on CD40/CD40L
protein and mRNA expression in CRL1730 cells
The effects of maternal sera from healthy pregnant women
and PE patients on CD40 and CD40L protein and mRNA
expression were next determined using flow cytometry and
RT-PCR analyses, respectively. The expression of both
CD40 (Figure 5A) and CD40L (Figure 5B) was observed inoptosis was determined in CRL1730 cells treated with serum from
ethods. A) 24-h normal pregnant group; B) 48-h normal pregnant
; and F) 72-h PE group. A representative image from three
Figure 4 CRL1730 cell apoptosis after culture in the presence
of normal pregnant or PE sera. Continuous variables were
presented as mean± SD and comparison of effect between two
groups over time was performed by repeated measures of ANOVA
and difference in apoptotic rate between two groups over time was
significant (P< 0.001). n = 20 for each group
Figure 6 Upregulation of CD40/CD40L expression upon
stimulation with PE sera. CD40/CD40L mRNA expression was
determined in CRL1730 cells treated with serum from normal and PE
pregnant women using RT-PCR. Lane 1) 24-h normal pregnant
group; lane 2) 24-h PE group; lane 3) 48-h normal pregnant group;
lane 4) 48-h PE group; lane 5) 72-h normal pregnant group; and lane
6) 72-h PE group. A representative image from three independent
experiments is shown
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ences in the extent of expression were noted (Figure 5).
Compared with the control group, CD40/CD40LFigure 5 Effects of normal pregnant and PE sera on CD40/
CD40L protein expression in CRL1730 cells. CD40 (A) and CD40L
(B) protein expression in CRL1730 cells after treatment with normal
pregnant and PE sera. Continuous variables were presented as
mean± SD and comparison of effect between two groups over time
was performed by repeated measures of ANOVA and difference in
CD40 and CD40L protein expression in CRL1730 cells between two
groups over time was significant (P< 0.001). n = 20 for each groupexpression increased significantly in the PE group (P
<0.01). No statistical difference in the expression of CD40/
CD40L was found in the control over time (P >0.05); how-
ever, expression of CD40/CD40L at 24 h was higher than
observed at 48 and 72 h in the PE group (P <0.05).Figure 7 Effects of normal pregnant and PE sera on CD40/
CD40L mRNA expression in CRL1730 cells. Expression of CD40
(A) and CD40L (B) mRNA in CRL1730 cells cultured in the presence
of sera from normal pregnant patients or those with PE. Results
were presented as mean± SD and comparison of effect between
two groups over time was performed by repeated measures of
ANOVA and difference in expression of CD40 and CD40L mRNA in
CRL1730 cells cultured between two groups over time was
significant (P< 0.001). n = 20 for each group
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upregulated expression of CD40 and CD40L mRNA
upon stimulation with PE maternal sera (Figures 6 and
7). CD40 and CD40L mRNA expression was significantly
greater in the PE group than in the control group.
CD40/CD40L expression was significantly higher at 24 h
than at 48 and 72 h (P <0.01), and CD40 expression was
significantly decreased at 72 h as compared to 48 h (P
<0.05; Figure 7 A&B). These results indicated that the
upregulation of CD40/CD40L expression by maternal
sera isolated from PE patients occurs at an early stage.
Discussion
Studies suggest that endothelial cell dysfunction is the
key pathophysiology underlying PE [15]; it may even be
an example of an endothelial damage disease [4]. Oxida-
tive stress is a common inducer of endothelial cell dam-
age, resulting in altered function [16]. Inflammatory
mediators (e.g., tumor necrosis factors, interleukin-6,
very low density lipoproteins, etc.) may trigger oxidative
stress and result in endothelial damage.
Various pathogenic factors can cause placental ischemia
and hypoxia, triggering the release of vasoactive sub-
stances. Systemic small vessel spasm and injury ensues,
damaging vascular endothelial cells. Placental oxidative
stress in PE is also associated with increased anti-angio-
genic factors, including soluble fms-related tyrosine kin-
ase-1 (sFlt-1) and soluble endoglin, which may be due to
overexpression of growth arrest and DNA damage-indu-
cible 45 alpha (Gadd45α) and excessive activation of p38
mitogen-activated protein kinase (MAPK); knockdown of
their expression resulted in decreased endothelial cell
apoptosis and oxidative stress and increased in vitro
angiogenesis [17]. Further studies will assess the role of
Gadd45α and p38 in endothelial cell functional changes
observed upon stimulation with PE sera.
Increased serum markers of endothelial cell dysfunc-
tion, including E-selectin and von Willebrand factor,
have been observed in patients with PE [18]. In the
present study, altered CRL1730 cell morphology, growth
and apoptosis were observed upon treatment with PE
sera, which is indicative of endothelial cell dysfunction.
However, endothelial cell function was not directly ana-
lyzed; therefore, further studies are necessary to deter-
mine the full extent of the damage induced by PE sera.
Szarka et al. [19] showed that the levels of pro-inflam-
matory cytokines, chemokines, and adhesion molecules
were elevated in the maternal serum of PE patients com-
pared to healthy pregnant women. The excessive sys-
temic inflammatory response might be one of the factors
leading to the endothelial dysfunction/activation.
Increased serum heat shock protein 70 (Hsp70) levels
have been observed in patients with early-onset or se-
vere PE [20]. Hsp70 along with other pro-apoptoticproteins have been shown to mediate endothelial cell
apoptosis in PE subjects [21], which is in agreement with
the increased CRL1730 cell apoptosis upon culture with
maternal sera obtained from PE patients. However, the
apoptosis rate decreased over time. Although a higher
concentration of soluble CD40L was shown to protect
maternal immune cells bearing CD40 receptor from Fas-
mediated apoptosis [22], the decreased apoptosis rate
could be not explained by decreased CD40/CD40L in
the present study. Degradation and/or catabolism of
Hsp70 and other pro-apoptotic molecules present in the
PE serum may account for this observation.
In the present study, increased expression of CD40/
CD40L was observed in the early stage of stimulation
with PE sera, suggesting the involvement of CD40/
CD40L in the occurrence of early-onset PE. This obser-
vation is consistent with the involvement of CD40/
CD40L in early coronary atherosclerosis [23]. It is also
consistent with the study of Darmochwal-Kolarz et al.
[24] in which the serum concentration of soluble CD40L
was significantly higher in PE women as compared to
healthy pregnant women. Its reduced expression in
healthy pregnant women as compared to non-pregnant
women is suggestive of a decreased innate immunity in
normal pregnancy that is disturbed in PE [24].
The present study has limitations. Firstly, cell growth
was measured using an MTT assay, which provides a
measure of mitochondrial activity and requires cell di-
gestion; however, the actual cell numbers were not quan-
tified due to limited blood sample volume. Further
studies using hemocytometry or flow cytometry will be
undertaken to directly evaluate cell growth. Further-
more, although changes in CRL1730 growth, apoptosis,
and CD40/CD40L expression were observed upon
stimulation with PE sera, the serum factors responsible
for those changes were not determined in the present
study due to the limited blood sample volume obtained.
However, further investigations into the responsible fac-
tors will be undertaken in future studies. Finally, the role
of CD40/CD40L expression will be fully elucidated using
neutralization or knockdown studies.
Conclusion
In summary, the upregulation of CD40/CD40L expression
in endothelial cells treated with maternal sera from PE
patients coincides with vascular endothelial cell apoptosis.
Further studies are necessary to determine the factor(s)
mediating these effects as well as elucidate their role in
the pathogenesis of PE.
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